MAP2K7 and neoplasm: In contrast, the baseline PD-L1− subgroup showed a significant rise in PD-L1 expression from RAF/MEK inhibitor pre-treatment to progression despite the increase in the tumor-infiltrating lymphocytes, suggesting T-cell exhaustion is a potential mechanism for immune evasion under RAF/MEK inhibition [51].